These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Sciarra A; Cardi A; Di Silverio F Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347 [TBL] [Abstract][Full Text] [Related]
4. Antiandrogen monotherapy in the management of advanced prostate cancer. Kaisary AV Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906 [TBL] [Abstract][Full Text] [Related]
5. The role of antiandrogen monotherapy in the treatment of prostate cancer. Anderson J BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397 [TBL] [Abstract][Full Text] [Related]
6. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708 [TBL] [Abstract][Full Text] [Related]
10. Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ; Holdsworth MT Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470 [TBL] [Abstract][Full Text] [Related]
11. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Boccon-Gibod L Eur Urol; 1998; 33(2):159-64. PubMed ID: 9519357 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Mahler C; Verhelst J; Denis L Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622 [TBL] [Abstract][Full Text] [Related]
13. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793 [TBL] [Abstract][Full Text] [Related]
14. Bicalutamide monotherapy for early stage prostate cancer: an update. Iversen P J Urol; 2003 Dec; 170(6 Pt 2):S48-52; discussion S52-4. PubMed ID: 14610410 [TBL] [Abstract][Full Text] [Related]
15. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428 [TBL] [Abstract][Full Text] [Related]
17. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Baert L; Tammela T; Chamberlain M; Carroll K; Gotting-Smith K; Blackledge GR Urology; 1998 Mar; 51(3):389-96. PubMed ID: 9510340 [TBL] [Abstract][Full Text] [Related]
18. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Blackledge G; Kolvenbag G; Nash A Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095 [TBL] [Abstract][Full Text] [Related]
19. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer. Wellington K; Keam SJ Drugs; 2006; 66(6):837-50. PubMed ID: 16706554 [TBL] [Abstract][Full Text] [Related]
20. Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy? Abrahamsson PA Eur Urol; 2001; 39 Suppl 1():22-8. PubMed ID: 11114597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]